Factor XI Replacement Dosing for Hemophilia C
For major surgery or acute bleeding in Factor XI deficiency, administer fresh frozen plasma (FFP) at 15-20 mL/kg to achieve target FXI levels of 10-20% for preoperative prophylaxis, or 30-45% for active major bleeding, combined with tranexamic acid as an adjunct. 1
Dosing Strategy by Clinical Scenario
Major Surgery (Preoperative)
- FFP dose: 15-20 mL/kg to maintain FXI levels at 10-20% of normal 1
- FXI concentrate (if available in Europe): 15-25 IU/kg 2, 3
- Administer before surgical incision
- Add tranexamic acid for procedures involving mucosal surfaces or high fibrinolytic activity 1
Active Major Bleeding (Intraoperative/Acute)
- Target FXI levels: 30-45% of normal 1
- FFP: Higher volumes may be required to achieve these levels
- FXI concentrate: 15-25 IU/kg if available 2, 3
- Consider rFVIIa as rescue therapy if bleeding persists despite replacement 1
Minor Procedures or Bleeding
- Tranexamic acid alone may suffice without factor replacement 1
- Reserve FFP/FXI concentrate for patients with severe deficiency (FXI <10%) and positive bleeding history
Critical Pharmacokinetic Considerations
FXI has a prolonged half-life of 40-70 hours 1, which means:
- Repeat dosing is typically needed only on postoperative day 3 for major surgery 2
- Less frequent dosing compared to FVIII or FIX
- Monitor levels if available, as plasma response to FFP is variable 4
Geographic Availability Caveat
In the United States, FFP is the only available FXI source 1. Plasma-derived FXI concentrate exists only in Europe 1, 5. This fundamentally determines your replacement strategy based on practice location.
Risk Assessment Framework
The most recent guidelines 1 emphasize that FXI levels do not reliably predict bleeding risk 6, 7, 8. Instead, stratify patients by:
- Personal bleeding history (most predictive factor) 1, 7
- Family bleeding history within kinships 1
- Surgical bleeding risk (high-fibrinolytic procedures like ENT, dental, urologic carry higher risk) 1, 7
- FXI level as secondary consideration:
Monitoring During Treatment
- aPTT: Will be prolonged in deficiency but doesn't predict bleeding 1
- Traditional coagulation tests: PT, aPTT, fibrinogen, platelet count at baseline and if bleeding occurs 1
- Viscoelastic testing (TEG/ROTEM): Provides real-time assessment but doesn't measure FXI specifically; use to guide transfusion decisions, not to exclude deficiency 1
- FXI activity levels: Ideal but results take time; don't wait for results if active bleeding 1
Major Safety Warning
Thrombotic risk exists with FXI replacement, particularly with FXI concentrate 5. One fatal pulmonary embolism was reported in a postmarketing study 5. This risk is heightened in patients with:
- Pre-existing thrombotic risk factors
- Higher dosing regimens
- Older age
Use the minimum effective dose and avoid prophylactic replacement in patients with negative bleeding history undergoing low-risk procedures 5.
Special Population: Pregnancy
For pregnant women with severe FXI deficiency (<1%):
- FFP or FXI concentrate before neuraxial anesthesia 1
- Tranexamic acid postpartum 1
- For mild deficiency with negative bleeding history: tranexamic acid alone at delivery 1
- Postpartum hemorrhage rates are increased in this population 1
When NOT to Replace
Do not routinely replace FXI for:
- Patients with FXI >10% and negative bleeding history undergoing low-risk procedures 1
- Minor procedures when tranexamic acid alone is appropriate 1
- Previous uneventful surgery does NOT exclude future bleeding risk, but negative personal history is reassuring 1
Rescue Therapy
If bleeding persists despite adequate FXI replacement: